There was a statistically significant difference between each albiglutide treatment group and placebo for change from baseline in HbA1c at week 16 , with treatment effects of -0.89 % for 15mg weekly , -1.55 % for 30mg weekly , and -1.10 % for 30mg biweekly ( P < 0.0001 for all groups vs placebo ) .